Displaying 1 - 10 of 241
Alternative Name: 11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)
User: Male
Hormonal: Yes
Delivery Method: Injectable, Oral
Developer: BIOQUAL, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Smaller/Nulliparous Copper IUD, Liberté TT380 Short, Micro T
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: Abhydrolase Domain Containing 2, 2-Arachidonoylglycerol Hydrolase, Monoacylglycerol Lipase ABHD2, Lung Alpha/Beta Hydrolase 2, Protein PHPS1-2, LABH2, Alpha/Beta Hydrolase Domain Containing Protein 2
Target
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Acrosomal Vesicle Protein 1, Acrosomal Protein SP-10, Sperm Protein 10, D11S4365, SPACA2, SP-10
Target
User: Female
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: GnRH II Receptor Antagonists
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Androglobin, Calpain-7-Like Protein, C6orf103, Chromosome 6 Open Reading Frame 103, CAPN16, CAPN7L
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
Development Phase: Discovery and Early Development
Alternative Name: AF-2364
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Injectable, Oral, Other
Developer: Population Council
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Oral
Developer: University of Washington, University of Minnesota
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 11 - 20 of 68
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Norfolk State University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: University of Cincinnati
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Murdoch University
Development Stage: Prototype Development
Alternative Name: Bromodomain Testis Associated, Cancer/Testis Antigen 9, Bromodomain Testis-Specific Protein, Bromodomain, Testis-Specific, RING3-Like Protein, CT9, SPGF21, BRD6
Target
User: Male
Hormonal: No
Delivery Method: Injectable, Oral
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Bar-Ilan University
Development Stage: Compound ID/Selection
Alternative Name: Calrecticulin 3, Calsperin, Cancer/Testis Antigen 93, Calreticulin-2, CRT2, Testis Secretory Sperm-Binding Protein Li 226n, CMH19, CT93
Target
User: Male
Hormonal: No
Development Stage: Target Validation
Target
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital, Emergency
Developer: Hydra Biosciences, University of Minnesota, University of California at Berkeley, Harvard University, Dare BioScience Inc.
Development Stage: Lead Optimization
Alternative Name: Cyclin-dependent kinases (CDKs)
Target
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota, Moffitt Cancer Center at University of South Florida
Development Stage: Target Identification
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: National Research Institute for Family Planning in Beijing
Development Stage: Prototype Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization

Pages

Displaying 1 - 10 of 122
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Oral
Developer: University of Washington, University of Minnesota
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem, Inc.
Development Stage: Phase III
Alternative Name: ARC; triple hormone contraceptive; Triple OC
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: ANI Pharmaceuticals, Pantarhei Bioscience
Development Stage: Phase II
Alternative Name: Suspensories
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Testicular
Developer: Centre Hospitalier Universitaire de Toulouse, France
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Yale University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Peking University, Institute of Biomedical Engineering at Chinese Academy of Medical College
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: University of Washington
Development Stage: Pre-clinical
Alternative Name: BDADs
User: Female, Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Oral
Developer: Focused Scientific, University of Washington
Development Stage: Pre-clinical

Pages

Displaying 1 - 10 of 51
Alternative Name: Smaller/Nulliparous Copper IUD, Liberté TT380 Short, Micro T
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: SRA/WHO PQ Approved
Alternative Name: Nestorone + Ethinyl Estradiol One-Year Contraceptive Vaginal Ring, NES + EE Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Population Council, NICHD, WHO, USAID, NIH, Bill & Melinda Gates Foundation, Avis and Clifford Barrus Medical Foundation
Development Stage: SRA/WHO PQ Approved
Alternative Name: SILCS Diaphragm
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Barrier
Developer: PATH, CONRAD, SILCS, Inc., Kessel Marketing & Vertriebs GmbH
Development Stage: SRA/WHO PQ Approved
Alternative Name: Saheli; Ormeloxifene
User: Female
Hormonal: No
Duration Type: Short-acting, Emergency
Delivery Method: Oral
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Chongqing Medical Equipment Factory Co., Ltd.
Development Stage: Marketed
Alternative Name: Nanocomposite Copper (Cu) IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tongji Medical College at Huazhong University of Science and Technology
Development Stage: Marketed
Alternative Name: l'Amour®; Jeitosa®
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Concept Foundation, Sun Pharmaceuticals, India, WHO HRP, PT. Tunggal Idaman Abdi
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Injectable
Developer: DKT International, PT Harsen
Development Stage: Marketed

Pages

CSV